Mesa Laboratories, Inc. - 10-K Summary (Fiscal Year Ended March 31, 2011)
Business Context and Reporting Period
This report covers the fiscal year ended March 31, 2011, for Mesa Laboratories, Inc. (NASDAQ: MLAB), a Colorado-based manufacturer of electronic measurement systems and disposable products. The company operates two primary divisions: Instrumentation (data loggers, medical meters, torque testing, fluid measurement) and Biological Indicators (sterility assurance products). The reporting period was defined by significant growth through the acquisitions of SGM Biotech, Inc. (April 2010) and the biological indicator product line of Apex Laboratories, Inc. (December 2010).
Key Financial Metrics
| Metric | Fiscal 2011 | Fiscal 2010 |
|---|---|---|
| Net Sales | $32,826,000 | $21,929,000 |
| Gross Profit | $19,568,000 | $13,194,000 |
| Gross Margin | 60% | 60% |
| Operating Income | $9,864,000 | $7,368,000 |
| Net Income | $6,183,000 | $4,769,000 |
| Diluted EPS | $1.86 | $1.45 |
| Cash and Equivalents | $3,546,000 | $10,471,000 |
| Total Debt (Current + Long Term) | $6,500,000 | $0 |
| Current Ratio | 1.7:1 | 11:1 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 50% to $32.8 million, driven primarily by the inclusion of SGM Biotech ($7.6M contribution) and Apex Laboratories ($0.9M contribution), alongside organic growth in the Biological Indicator segment.
- Profitability: Net income rose 30% to $6.2 million. However, net profit margin decreased from 22% to 19% due to increased amortization expenses from acquisitions and lower gross margins in the expanded Biological Indicator segment.
- Liquidity and Leverage: The company shifted from a net cash position to a leveraged balance sheet. Cash reserves dropped by approximately $6.9 million to fund acquisitions. Total debt increased to $6.5 million, consisting of a $4.0 million revolving line of credit (fully utilized) and a $2.5 million reducing term loan.
- Operating Expenses: Selling, General, and Administrative (SG&A) expenses increased significantly ($2.0M increase) due to higher headcount (177 employees vs. 112), salary increases, and $744,000 in additional amortization.
Outlook, Risks, and Management Commentary
Management Commentary: Management expects gross margins to improve in fiscal 2012 following the consolidation of Torqo manufacturing in-house and the full integration of Apex products. The company plans to use surplus cash flow to retire debt and maintain dividends, which were increased to $0.12 per share in the latter half of the year. Stock buybacks have been restricted due to lower cash positions and higher debt levels.
Risks and Contingencies:
- Debt Service: The company faces significant debt maturities, with $5.0 million due in fiscal 2012. Interest rates are variable with a 3.25% floor.
- Integration Risk: Success depends on effectively integrating acquired businesses (SGM, Apex) and realizing projected synergies.
- Competition: Intense competition exists in both instrumentation and biological indicator markets from larger, well-capitalized firms.
- Regulatory: Products are subject to FDA regulations; non-compliance could result in fines or suspension of sales.
Investor Verification Checklist
- Debt Covenants: Verify compliance with restrictive covenants on the $7 million credit facility and the ability to service $5 million in principal payments due in fiscal 2012.
- Margin Trends: Monitor gross margin performance in the Biological Indicator segment to ensure it stabilizes as projected for fiscal 2012.
- Amortization Impact: Confirm the trajectory of amortization expenses ($1.48M estimated for fiscal 2012) and its effect on operating income.
- Cash Flow: Assess operating cash flow generation ($8.9M in FY2011) against capital expenditure and debt repayment requirements.
- Customer Concentration: While no single customer exceeded 10% in FY2011, verify that the consolidation of the dialysis industry does not lead to increased concentration risk.